SG11201504038XA - Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction - Google Patents

Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction

Info

Publication number
SG11201504038XA
SG11201504038XA SG11201504038XA SG11201504038XA SG11201504038XA SG 11201504038X A SG11201504038X A SG 11201504038XA SG 11201504038X A SG11201504038X A SG 11201504038XA SG 11201504038X A SG11201504038X A SG 11201504038XA SG 11201504038X A SG11201504038X A SG 11201504038XA
Authority
SG
Singapore
Prior art keywords
regulatory elements
fetal hemoglobin
distal regulatory
targeting bcl11a
reinduction
Prior art date
Application number
SG11201504038XA
Inventor
Stuart H Orkin
Daniel E Bauer
Jian Xu
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of SG11201504038XA publication Critical patent/SG11201504038XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201504038XA 2012-11-27 2013-11-27 Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction SG11201504038XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730369P 2012-11-27 2012-11-27
US201261730323P 2012-11-27 2012-11-27
US201361776144P 2013-03-11 2013-03-11
US201361889174P 2013-10-10 2013-10-10
PCT/US2013/072236 WO2014085593A1 (en) 2012-11-27 2013-11-27 Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction

Publications (1)

Publication Number Publication Date
SG11201504038XA true SG11201504038XA (en) 2015-06-29

Family

ID=50828461

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202110062SA SG10202110062SA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
SG11201504038XA SG11201504038XA (en) 2012-11-27 2013-11-27 Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
SG10201704008RA SG10201704008RA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202110062SA SG10202110062SA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704008RA SG10201704008RA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Country Status (18)

Country Link
US (4) US9822355B2 (en)
EP (2) EP3502240B1 (en)
JP (2) JP6542124B2 (en)
KR (1) KR102240555B1 (en)
CN (2) CN104955943B (en)
AU (3) AU2013352156B2 (en)
BR (1) BR112015011995B1 (en)
CA (1) CA2892860C (en)
DK (2) DK2925864T3 (en)
ES (2) ES2708948T3 (en)
HK (1) HK1215720A1 (en)
IL (1) IL238949B (en)
MX (1) MX361412B (en)
PT (2) PT3502240T (en)
SA (1) SA515360489B1 (en)
SG (3) SG10202110062SA (en)
WO (1) WO2014085593A1 (en)
ZA (1) ZA201504004B (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
SG10201801782PA (en) * 2013-09-04 2018-04-27 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
PL3492593T3 (en) * 2013-11-13 2022-04-19 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CA2946309C (en) 2014-04-25 2021-11-09 Michael MILSOM Synthetic bcl11a micrornas for treating hemoglobinopathies
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev Nmda receptor antagonists for treating gaucher disease
EP3262171A2 (en) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of hemoglobinopathies
US20180200387A1 (en) 2015-02-23 2018-07-19 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
WO2016182917A1 (en) * 2015-05-08 2016-11-17 Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
BR112017024115A2 (en) * 2015-05-12 2018-08-07 Sangamo Therapeutics Inc nuclease-mediated gene expression regulation
WO2016183280A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
JP7396783B2 (en) 2015-06-09 2023-12-12 エディタス・メディシン、インコーポレイテッド CRISPR/CAS-related methods and compositions for improving implantation
KR20180063881A (en) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 Compositions and methods for the treatment of cancer
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
WO2017077394A2 (en) 2015-11-04 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
CA3009727A1 (en) * 2015-12-28 2017-07-06 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
AU2017204950A1 (en) 2016-01-06 2018-08-16 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
EP3405024B1 (en) 2016-01-21 2022-12-28 The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Parthenocarpic plants and methods of producing same
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
CN108883136A (en) 2016-02-12 2018-11-23 蓝鸟生物公司 VCN enhancer combination object and its application method
EP3414321B8 (en) 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
EP3430142A1 (en) * 2016-03-14 2019-01-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
US20200330609A1 (en) * 2016-04-18 2020-10-22 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
CN110234765A (en) 2016-11-28 2019-09-13 耶达研究及发展有限公司 Isolated polynucleotides and polypeptides and make the method for being used to express interested expression product
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018122771A1 (en) 2016-12-29 2018-07-05 Ukko Inc. Methods for identifying and de-epitoping allergenic polypeptides
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
JP7191388B2 (en) 2017-03-23 2022-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Methods of treating psychiatric stress disorders
EP3622070A2 (en) * 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combination therapy for the treatment of cancer
CN111801345A (en) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited Compositions and methods for improving alcohol tolerance in yeast
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (en) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 Use of adenosine base editor
CN109722415B (en) * 2017-10-27 2021-01-26 博雅辑因(北京)生物科技有限公司 Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with improved properties
WO2019147302A1 (en) * 2018-01-26 2019-08-01 Bauer Daniel E Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3749768A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
SG11202008956XA (en) 2018-03-14 2020-10-29 Editas Medicine Inc Systems and methods for the treatment of hemoglobinopathies
WO2020008412A1 (en) 2018-07-04 2020-01-09 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
WO2020112979A2 (en) * 2018-11-30 2020-06-04 Bauer Daniel E Therapeutic gene editing for elane-associated disease
CN109486850B (en) * 2018-12-04 2021-05-25 厦门大学 Optogenetic tool for UV-B light-down regulation of chromatin long-distance interaction
MX2021010611A (en) 2019-03-05 2021-11-12 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Genome-edited birds.
WO2020191243A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111939271A (en) * 2019-04-30 2020-11-17 博雅辑因(北京)生物科技有限公司 Method for predicting treatment effectiveness of hemoglobinopathy
EA202192931A1 (en) * 2019-04-30 2022-02-22 Эдиджен Инк. METHOD FOR PREDICTION OF THE EFFICIENCY OF HEMOGLOBINOPATHY TREATMENT
EP3994268A1 (en) 2019-07-04 2022-05-11 Ukko Inc. De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev Systems and methods for identifying cells that have undergone genome editing
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
CN111705044B (en) * 2020-05-23 2022-12-27 南京大学 Construction of novel controllable high-activity G quadruplex DNA enzyme
JP2023545999A (en) 2020-10-05 2023-11-01 プロタリクス リミテッド DICER-like knockout plant cells
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
JP2023550979A (en) 2020-11-26 2023-12-06 ウッコ インコーポレイテッド Modified high molecular weight glutenin subunits and uses thereof
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
KR20230132472A (en) 2020-12-18 2023-09-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Composition for use in the treatment of CHD2 haploid dysfunction and method for determining the same
EP4337197A1 (en) 2021-05-10 2024-03-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmaceutical compositions for treating neurological conditions
EP4337232A1 (en) * 2021-05-13 2024-03-20 The Children's Medical Center Corporation Methods for stratifying subjects for fetal hemoglobin reinduction
JP2024534404A (en) 2021-06-13 2024-09-20 イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド How to reprogram human cells
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
WO2023012584A2 (en) 2021-08-03 2023-02-09 Genicity Limited Engineered tcr complex and methods of using same
CA3234612A1 (en) 2021-10-14 2023-04-20 Weedout Ltd. Methods of weed control
WO2023240282A1 (en) 2022-06-10 2023-12-14 Umoja Biopharma, Inc. Engineered stem cells and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5731156A (en) * 1996-10-21 1998-03-24 Applied Imaging, Inc. Use of anti-embryonic hemoglobin antibodies to identify fetal cells
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
CZ308053B6 (en) 2000-12-01 2019-11-27 Max Planck Gesellschaft Isolated double-stranded RNA molecule, process for producing it and its use
DK2284266T3 (en) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc SIRNA MOLECULE MOD TP53
ES2348868T3 (en) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY.
KR20070085113A (en) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20080051431A1 (en) 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
US9051391B2 (en) 2007-06-11 2015-06-09 Takara Bio Inc. Method for expression of specific gene
GB0713183D0 (en) 2007-07-06 2007-08-15 King S College London Method
WO2010030963A2 (en) 2008-09-15 2010-03-18 Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
EP2509418A4 (en) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Methods and low dose regimens for treating red blood cell disorders
JP2011135864A (en) * 2009-12-30 2011-07-14 Korea Univ Research & Business Foundation Composition for retrodifferentiating somatic cell to embryonic stem cell-like cell, by using oct4 in combination with bmi1 or upstream regulator thereof, and method for generating embryonic stem cell-like cell using the same
EP3502254A1 (en) 2010-04-23 2019-06-26 Cold Spring Harbor Laboratory Novel structurally designed shrnas
WO2012073047A2 (en) 2010-12-03 2012-06-07 Genome Research Limited Compositions and methods
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012170911A2 (en) 2011-06-10 2012-12-13 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
KR102011532B1 (en) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. Compounds for improved viral transduction
ES2641840T3 (en) 2012-02-24 2017-11-14 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
DK2925864T3 (en) * 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
KR20150105633A (en) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 Engineering of systems, methods and optimized guide compositions for sequence manipulation
WO2014093965A1 (en) 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
CN116083487A (en) 2013-05-15 2023-05-09 桑格摩生物治疗股份有限公司 Methods and compositions for treating genetic conditions
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
PL3492593T3 (en) 2013-11-13 2022-04-19 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
CN104955119B (en) 2014-03-26 2019-11-26 南京中兴新软件有限责任公司 A kind of method for switching network based on flow, device and terminal
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
CA2946309C (en) 2014-04-25 2021-11-09 Michael MILSOM Synthetic bcl11a micrornas for treating hemoglobinopathies
EP3134434A4 (en) 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
EP3160980B1 (en) 2014-05-28 2020-05-20 The Regents of the University of California HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
EP3294879A4 (en) 2015-05-14 2019-02-20 University of Southern California Optimized gene editing utilizing a recombinant endonuclease system
CN108136014A (en) 2015-08-31 2018-06-08 蓝鸟生物公司 Anti- sialic acid TN Chimeric antigen receptors
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
EP3414321B8 (en) 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery

Also Published As

Publication number Publication date
CN109554350B (en) 2022-09-23
AU2021218012A1 (en) 2021-09-09
ES2708948T3 (en) 2019-04-12
JP2015536657A (en) 2015-12-24
US11542493B2 (en) 2023-01-03
US20180119130A1 (en) 2018-05-03
EP2925864B1 (en) 2018-10-31
IL238949B (en) 2019-06-30
EP2925864A4 (en) 2016-07-13
KR20150107726A (en) 2015-09-23
SA515360489B1 (en) 2016-12-25
SG10201704008RA (en) 2017-06-29
AU2013352156A1 (en) 2015-06-11
PT2925864T (en) 2019-02-06
DK3502240T3 (en) 2021-08-09
US20230348887A1 (en) 2023-11-02
CN104955943A (en) 2015-09-30
SG10202110062SA (en) 2021-11-29
IL238949A0 (en) 2015-07-30
AU2018278850B2 (en) 2021-05-27
AU2013352156B2 (en) 2018-12-06
US10472619B2 (en) 2019-11-12
KR102240555B1 (en) 2021-04-16
WO2014085593A1 (en) 2014-06-05
EP2925864A1 (en) 2015-10-07
EP3502240B1 (en) 2021-05-05
JP2018085987A (en) 2018-06-07
ZA201504004B (en) 2016-11-30
BR112015011995B1 (en) 2023-02-07
BR112015011995A2 (en) 2017-07-11
JP6633602B2 (en) 2020-01-22
MX361412B (en) 2018-12-05
CA2892860A1 (en) 2014-06-05
US20200087651A1 (en) 2020-03-19
US9822355B2 (en) 2017-11-21
MX2015006528A (en) 2016-07-13
HK1215720A1 (en) 2016-09-09
DK2925864T3 (en) 2019-02-11
US20150307867A1 (en) 2015-10-29
ES2884925T3 (en) 2021-12-13
CN109554350A (en) 2019-04-02
JP6542124B2 (en) 2019-07-10
EP3502240A1 (en) 2019-06-26
PT3502240T (en) 2021-08-11
AU2018278850A1 (en) 2019-01-17
AU2021218012B2 (en) 2023-06-29
CA2892860C (en) 2023-01-03
CN104955943B (en) 2018-09-25

Similar Documents

Publication Publication Date Title
HK1215720A1 (en) Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction bcl11a
EP2916905A4 (en) Medical connector
EP2842540A4 (en) Medical connector
EP2837341A4 (en) Medical manipulator
EP2837354A4 (en) Medical manipulator
ZA201300386B (en) Connector for medical lines
EP2837340A4 (en) Medical manipulator
EP2812777A4 (en) Character-string completion
GB201218307D0 (en) Patient monitor
EP2815691A4 (en) Endoscope
PL2882487T3 (en) Connector for medical use
EP2692278A4 (en) Endoscope
EP2939632A4 (en) Surgical robot
EP2891448A4 (en) Endoscope
EP2820999A4 (en) Endoscope
EP2656779A4 (en) Endoscope
EP2837320A4 (en) Endoscope
EP2805664A4 (en) Endoscope
EP2868252A4 (en) Endoscope
EP2835093A4 (en) Endoscope
EP2881048A4 (en) Medical manipulator
EP2735260A4 (en) Endoscope
HK1211480A1 (en) External preparation for skin
EP2799000A4 (en) Endoscope
EP2856924A4 (en) Endoscope